SecBot SecBot
8-K ·Filed Apr 29, 2026

ANIK

Anika Therapeutics, Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001171843-26-002799
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

Monitor continued operational improvement and FDA updates on Hyalofast and Cingal. Maintained guidance and strong adjusted EBITDA suggest restructuring traction, but GAAP loss widening remains a concern. The stock may trade on adjusted profitability improvement rather than GAAP EPS miss.

DirectionMixed
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$12.39
T+0 close · Apr 29, 2026 · via day close
Latest settled
+20.66%
T+60 · $14.95
Vs SPY
+16.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $12.39entry
  2. T+1 · 7mo ago +0.48%α −0.54% · $12.45
  3. T+5 · 7mo ago +22.03%α +18.92% · $15.12
  4. T+20 · 6mo ago +20.26%α +14.21% · $14.90
  5. T+60 · 4mo ago +20.66%α +16.55% · $14.95

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Anika Therapeutics reported Q1 2026 revenue of $29.6M, up 13% YoY and beating consensus of $28.1M, but GAAP EPS of -$0.37 missed the -$0.21 consensus by 76%, driven by $4.9M in one-time severance costs. Adjusted EBITDA surged to $4.3M from $0.1M and guidance was maintained, while two directors resigned effective at the annual meeting.

Key Financial Metrics

EPS
−$0.37
est −$0.21 · -76.2%
Revenue
$29.6M
est $28.1M · +5.4% · +13.2% YoY
Rating
miss
Guidance
$114-$122.5 million
maintained
Free Cash Flow
-$6.3M
Gross Margin
64.2%

Key Facts

  • Q1 revenue $29.6M, +13% YoY, beat consensus $28.1M
  • GAAP diluted EPS from continuing ops -$0.37 vs consensus -$0.21 (miss)
  • Adjusted diluted EPS $0.27 vs -$0.06 prior year
  • Gross margin 64.2%, up 810 bps YoY from 56.1%
  • Adjusted EBITDA $4.3M vs $0.1M prior year
  • FY2026 guidance maintained: revenue $114-$122.5M
  • $15M share repurchase completed at avg $10.76/share
  • Two directors resign, board to shrink from 9 to 7 members

Financial Impact

Revenue beat of ~$1.5M (5.4%) vs consensus; EPS miss of $0.16 (-76%) vs consensus

revenueepsgross marginadjusted ebitda

Risk Factors

  • GAAP loss per share widened to -$0.37 from -$0.28
  • One-time severance costs of $4.9M obscuring underlying profitability
  • FDA approval uncertainty for Hyalofast PMA and Cingal NDA

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-002799
Document: f8k_042926.htm0001171843-26-002799
Document: 0001171843-26-002799-index-headers.html0001171843-26-002799
Document: 0001171843-26-002799-index.html0001171843-26-002799
Document: 0001171843-26-002799.txt0001171843-26-002799
8-K Data (Synthetic)0001171843-26-002799

Track record

13 reports on ANIK

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 6, 202610d ago 8-K Mixed 6/10 Entry $14.55 Now $12.92 −11.20% settles Feb 4
  2. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $21.42 Now $12.92 −39.68% settles Jan 21
  3. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $16.17 to $21.09 Now $12.92 −20.10% ▲ +30.43% +25.70% vs SPY
  4. Jul 14, 202617w ago 8-K Neutral 3/10 Entry $15.93 to $19.23 Now $12.92 −18.90% ▲ +20.72% +18.18% vs SPY
  5. Jun 23, 202620w ago 8-K Neutral 4/10 Entry $14.73 to $21.03 Now $12.92 −12.29% ▲ +42.77% +39.93% vs SPY
  6. Jun 11, 202622w ago Institutional Cluster Bearish 4/10 Entry $14.72 to $21.04 Now $12.92 +12.23% ▼ −42.93% −39.67% vs SPY
  7. Jun 8, 202623w ago DEFA14A Neutral 4/10 Entry $14.60 to $21.11 Now $12.92 −11.51% ▲ +44.59% +41.54% vs SPY
  8. Jun 1, 202624w ago DEFA14A Neutral 3/10 Entry $14.63 to $21.40 Now $12.92 −11.69% ▲ +46.27% +45.04% vs SPY
  9. Apr 30, 202628w ago Insider Cluster Mixed 5/10 Entry $14.85 to $16.17 Now $12.92 −13.00% ▲ +8.89% +7.41% vs SPY
  10. Apr 29, 202628w ago 8-K Mixed 6/10 Viewing Entry $12.39 to $14.95 Now $12.92 +4.28% ▲ +20.66% +16.55% vs SPY
Showing 10 of 13

US Market Status

Market Closed · Opens in 5h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026